Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 36Recruiting 25Completed 13Not yet recruiting 5Suspended 4Terminated 3Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 3Genitourinary 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1Advanced Glioblastoma 1

Interventions

Specimen Handling 62Magnetic Resonance Spectroscopy 44Cyclophosphamide 32Gemcitabine 29Carboplatin 27Biopsy 26pembrolizumab 23Radiotherapy 23Bevacizumab 23Paclitaxel 22venetoclax 21fludarabine 21Nivolumab 21Cisplatin 21Standard of Care 20Drug Therapy 20Capecitabine 20Oxaliplatin 19Radiosurgery 16Blood Specimen Collection 16Azacitidine 16Interviews as Topic 15Dexamethasone 15toripalimab 14cemiplimab 14Docetaxel 14tislelizumab 13Injections 13anlotinib 11Fluorouracil 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Radiotherapy, Intensity-Modulated × 90 days × Clear all
NCT07605364 2026-05-26

Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 2/3 Not yet recruiting
422 enrolled
CNS

Advanced Glioblastoma

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

University of Washington

Phase 1/2 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07441681 2026-05-04

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

NRG Oncology

Phase 3 Not yet recruiting
454 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07555860 2026-04-29

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
28 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07524413 2026-04-13

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
514 enrolled
Head & Neck

Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡